Related Experiment Videos
Experimental radiation synovectomy by 165Dy ferric hydroxide macroaggregate
Abstract:
The short half-life beta emitter 165Dy coprecipitated as a macroaggregate with ferric hydroxide (FHMA) has been shown to destroy knee synovium in the antigen-induced arthritic rabbit. Using 153Gd as a gamma tracer for leakage studies revealed that the leakage of this system from rabbit knee joints never exceeded 1.2% over 24 hours. This is such less than the leakage rates reported from any human studies or our rabbit studies using 198Au.
Insights
The novel ferric hydroxide macroaggregate (FHMA) containing the beta emitter 165Dy effectively destroys knee synovium in arthritic rabbits. Leakage from rabbit knee joints remained below 1.2%, indicating a safe and effective targeted radiation therapy.
Area of Science:
- Nuclear Medicine
- Radiopharmaceutical Therapy
- Rheumatology
Background:
- Antigen-induced arthritis is a significant cause of knee joint inflammation.
- Current treatments for arthritis can have systemic side effects.
- Targeted radiotherapy offers a potential localized treatment approach.
Purpose of the Study:
- To evaluate the efficacy of 165Dy-ferric hydroxide macroaggregate (FHMA) in destroying knee synovium in a rabbit model of antigen-induced arthritis.
- To assess the in vivo leakage of 165Dy-FHMA from rabbit knee joints.
Main Methods:
- Rabbits with antigen-induced arthritis were treated with 165Dy-FHMA.
- Leakage studies were performed using 153Gd as a gamma tracer.
- Leakage rates were quantified over a 24-hour period.
Main Results:
- 165Dy-FHMA demonstrated efficacy in destroying knee synovium.
- Leakage of the 153Gd tracer from rabbit knee joints did not exceed 1.2% over 24 hours.
- Leakage rates were significantly lower compared to previous studies using 198Au and human studies.
Conclusions:
- 165Dy-FHMA is a promising targeted radiotherapeutic agent for knee synovitis.
- The low leakage rate suggests a favorable safety profile for intra-articular injection.
- This approach offers a potential improvement over existing treatments for inflammatory joint diseases.